Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 3/2010

01-10-2010 | American Society of Breast Surgeons

Does Blue Dye Contribute to Success of Sentinel Node Mapping for Breast Cancer?

Authors: Taewoo Kang, MD, PhD, Min Yi, MD, Kelly K. Hunt, MD, Elizabeth A. Mittendorf, MD, Gildy V. Babiera, MD, Henry Kuerer, MD, PhD, Isabelle Bedrosian, MD, Rosa F. Hwang, MD, Anthony Lucci, MD, Funda Meric-Bernstam, MD

Published in: Annals of Surgical Oncology | Special Issue 3/2010

Login to get access

Abstract

Background

We sought to evaluate the utilization of blue dye in addition to radioisotope and its relative contribution to sentinel lymph node (SLN) mapping at a high-volume institution.

Methods

Using a prospectively maintained database, 3,402 breast cancer patients undergoing SLN mapping between 2002 and 2006 were identified. Trends in utilization of blue dye and results of SLN mapping were assessed through retrospective review. Statistical analysis was performed with Student t test and chi-square analysis.

Results

2,049 (60.2%) patients underwent mapping with dual technique, and 1,353 (39.8%) with radioisotope only. Blue dye use decreased gradually over time (69.8% in 2002 to 48.3% in 2006, p < 0.0001). Blue dye was used significantly more frequently in patients with lower axillary counts, higher body mass index (BMI), African-American race, and higher T stage, and in patients not undergoing skin-sparing mastectomy. There was no difference in SLN identification rates between patients who had dual technique versus radiocolloid alone (both 98.4%). Four (0.8%) of 496 patients who had dual mapping and a positive SLN had a blue but not hot node as the only involved SLN. None of these four had significant counts detected in the axilla intraoperatively. Nine (0.4%) of 2,049 patients who had dual mapping had allergic reactions attributed to blue dye.

Conclusions

Blue dye use has decreased with increasing institutional experience with SLN mapping. In patients with adequate radioactive counts in the axilla, blue dye is unlikely to improve the success of sentinel node mapping.
Literature
1.
McMasters KM, Tuttle TM, Carlson DJ, et al. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol. 2000;18:2560–6.PubMed
2.
Albo D, Wayne JD, Hunt KK, et al. Anaphylactic reactions to isosulfan blue dye during sentinel lymph node biopsy for breast cancer. Am J Surg. 2001;182:393–8.CrossRefPubMed
3.
Clarke D, Newcombe RG, Mansel RE. The learning curve in sentinel node biopsy: the ALMANAC experience. Ann Surg Oncol. 2004;11:211S–5S.PubMed
4.
Cody HS, III, Hill AD, Tran KN, Brennan MF, Borgen PI. Credentialing for breast lymphatic mapping: how many cases are enough? Ann Surg. 1999;229:723–6 (discussion 6–8).CrossRefPubMed
5.
Derossis AM, Fey J, Yeung H, et al. A trend analysis of the relative value of blue dye and isotope localization in 2,000 consecutive cases of sentinel node biopsy for breast cancer. J Am Coll Surg. 2001;193:473–8.CrossRefPubMed
6.
Raut CP, Daley MD, Hunt KK, et al. Anaphylactoid reactions to isosulfan blue dye during breast cancer lymphatic mapping in patients given preoperative prophylaxis. J Clin Oncol. 2004;22:567–8.CrossRefPubMed
7.
Raut CP, Hunt KK, Akins JS, et al. Incidence of anaphylactoid reactions to isosulfan blue dye during breast carcinoma lymphatic mapping in patients treated with preoperative prophylaxis: results of a surgical prospective clinical practice protocol. Cancer. 2005;104:692–9.CrossRefPubMed
8.
Albertini JJ, Lyman GH, Cox C, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA. 1996;276:1818–22.CrossRefPubMed
9.
Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220:391–8 (discussion 398–401).CrossRefPubMed
10.
Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol. 1993;2:335–9 (discussion 40).CrossRefPubMed
11.
Goyal A, Douglas-Jones A, Monypenny I, Sweetland H, Stevens G, Mansel RE. Is there a role of sentinel lymph node biopsy in ductal carcinoma in situ? Analysis of 587 cases. Breast Cancer Res Treat. 2006;98:311–4.CrossRefPubMed
12.
Degnim AC, Oh K, Cimmino VM, et al. Is blue dye indicated for sentinel lymph node biopsy in breast cancer patients with a positive lymphoscintigram? Ann Surg Oncol. 2005;12:712–7.CrossRefPubMed
13.
Cody HS, III, Klauber-Demore N, Borgen PI, Van Zee KJ. Is it really duct carcinoma in situ? Ann Surg Oncol. 2001;8:617–9.CrossRefPubMed
14.
Montgomery LL, Thorne AC, Van Zee KJ, et al. Isosulfan blue dye reactions during sentinel lymph node mapping for breast cancer. Anesth Analg. 2002;95:385–8 (table of contents).
15.
Leong SP, Donegan E, Heffernon W, Dean S, Katz JA. Adverse reactions to isosulfan blue during selective sentinel lymph node dissection in melanoma. Ann Surg Oncol. 2000;7:361–6.CrossRefPubMed
16.
Cimmino VM, Brown AC, Szocik JF, et al. Allergic reactions to isosulfan blue during sentinel node biopsy—a common event. Surgery. 2001;130:439–42.CrossRefPubMed
17.
18.
Masannat Y, Shenoy H, Speirs V, Hanby A, Horgan K. Properties and characteristics of the dyes injected to assist axillary sentinel node localization in breast surgery. Eur J Surg Oncol. 2006;32:381–4.CrossRefPubMed
Metadata
Title
Does Blue Dye Contribute to Success of Sentinel Node Mapping for Breast Cancer?
Authors
Taewoo Kang, MD, PhD
Min Yi, MD
Kelly K. Hunt, MD
Elizabeth A. Mittendorf, MD
Gildy V. Babiera, MD
Henry Kuerer, MD, PhD
Isabelle Bedrosian, MD
Rosa F. Hwang, MD
Anthony Lucci, MD
Funda Meric-Bernstam, MD
Publication date
01-10-2010
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue Special Issue 3/2010
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-010-1235-5

Other articles of this Special Issue 3/2010

Annals of Surgical Oncology 3/2010 Go to the issue

American Society of Breast Surgeons

Breast Conservation in Women with Multifocal-Multicentric Breast Cancer: Is It Feasible?

American Society of Breast Surgeons

Use of Breast MRI Surveillance in Women at High Risk for Breast Cancer: A Single-Institutional Experience

American Society of Breast Surgeons

Triple-Negative Breast Cancers: Unique Clinical Presentations and Outcomes

American Society of Breast Surgeons

Micrometastatic Disease and Isolated Tumor Cells as a Predictor for Additional Breast Cancer Axillary Metastatic Burden

American Society of Breast Surgeons

Use of Preoperative Magnetic Resonance Imaging for Invasive Lobular Cancer: Good, Better, but Maybe not the Best?

American Society of Breast Surgeons

Sentinel Lymph Node Biopsy is Precise After Primary Systemic Therapy in Stage II–III Breast Cancer Patients